Vasculitis & polymyalgia rheumatica
The use of non-TNF targeted biologics in Behçet’s disease: real-life data from the International AutoInflammatory Disease Alliance (AIDA) Network Behçet’s Disease Registry
Authors' conclusion
Biologics targeting IL-1, IL-6, IL-17 and the IL-12/23 pathways may offer therapeutic alternatives in BD patients unresponsive to TNF-α inhibitors.
Study context
- Population
- Patients with Behçet's disease (BD) who received any biologic other than TNF-α inhibitors at any point during follow-up, AIDA Network BD Registry36 female/29 male
- Participants
- 65 patients
- Exposure
- Non-TNF targeted biologics in BD
- Anakinran = 31
- Canakinumabn = 11
- Tocilizumabn = 15
- Ustekinumabn = 3
- Rituximabn = 5
- Outcome
- Partial or complete response by organ involvement
Methodological detailsmulticentre, international registry (AIDA Network BD Registry), real-life data
- Multicentre
- International registry (AIDA Network BD Registry)
- Real-life data
Main finding
As reported in the abstract
| Group | Mucocutaneous response | Musculoskeletal response | Ocular response |
|---|---|---|---|
| Anakinra | 34.7% | 73.3% | 77.7% |
Anakinra
Mucocutaneous response34.7%
Musculoskeletal response73.3%
Ocular response77.7%
- Tocilizumab: complete response in ocular and neurological involvement
- 5 of 6 patients
- Tocilizumab: worsening or no response in mucocutaneous manifestations
- 40%
Observational data: associations, not effects.
Safety
- No new major safety concerns across treatment groups
Original publication
The use of non-TNF targeted biologics in Behçet’s disease: real-life data from the International AIDA Network Behçet’s Disease Registry. Rheumatology (Oxford). Published 17 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →